Oseltamivir Phosphate
Brand names: Tamiflu, Oseltamivir Phosphate
At a glance
- Medicare prescriptions, 2024
- 162,904
- Medicare drug cost
- $6.7M
- Average cost per prescription
- $40.91
- Clinicians who prescribed it
- 6,842
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
TAMIFLU is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. Prophylaxis of influenza A and B in patients 1 year and older. Limitations of Use: Not a substitute for annual influenza vaccination. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. Not recommended for patients with end-stage renal disease not undergoing dialysis.
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 28.0%
- Internal Medicine 26.3%
- Nurse Practitioners 24.4%
- Physician Assistants 7.6%
- Geriatric Medicine 4.5%
- General Practice 2.5%
- Emergency Medicine 1.9%
- Hospitalist 0.8%
- Pulmonology 0.6%
- Hospice & Palliative Medicine 0.4%
- Infectious Disease 0.3%
- Nephrology (Kidney) 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 33% from 2019 to 2024.
Biggest change by state since 2019
- Arizona +10%
- Georgia −10%
- Florida −12%
- Illinois −19%
- Minnesota −21%
- Washington (smallest change) −67%
- Oregon (smallest change) −62%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amneal Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | yellow capsule, 14 mm | AMNEAL 264 |
| 45 mg | gray capsule, 14 mm | AMNEAL 265 |
| 75 mg | gray capsule, 18 mm | AMNEAL 266 |
Genentech, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | yellow capsule, 14 mm | ROCHE 30 MG |
| 45 mg | gray capsule, 14 mm | ROCHE 45 MG |
| 75 mg | yellow capsule, 18 mm | ROCHE 75 MG |
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | white capsule, 14 mm | N 1008 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 75 mg | yellow capsule, 18 mm | E555 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Feb 2024 · Amneal Pharmaceuticals of New York, LLC · Class II
Failed Impurities/Degradation Specifications: Out-of-specification test results. - Jan 2021 · Lupin Pharmaceuticals Inc. · Class III
Failed Impurities/Degradation Specifications; Out-of-specification test results observed for Impurity C at 9 month long-term stability time point.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.